Navigation Links
AEterna Zentaris Discloses Preliminary Phase 2 Trial Results for Perifosine in Combination with Radiotherapy for Non-Small Cell Lung Cancer
Date:6/8/2009

yeloma and metastatic colon cancer where, unlike the non-small cell lung cancer study design, perifosine is dosed 50mg or 100mg daily until progression. Recently, positive Phase 2 data for multiple myeloma and metastatic colon cancer were presented at ASH and ASCO meeting, respectively."

About Perifosine

Perifosine is a novel, first-in-class, oral anti-cancer agent that modulates several key signal transduction pathways, including Akt, MAPK, and JNK that have been shown to be critical for the survival of cancer cells. Perifosine has demonstrated single agent anti-tumor activity in Phase 1 and Phase 2 studies and is currently being studied as a single agent and in combination with several forms of anti-cancer treatments for various forms of cancer. Most recently, positive results were reported for the single agent use of perifosine in patients with advanced metastatic renal cancer and in combination with capecitabine for advanced metastatic colon cancer (placebo-controlled), as well as for perifosine in combination with bortezomib +/- dexamethasone in relapsed and refractory myeloma.

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. News releases and additional information are available at www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources t
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
2. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
3. AEterna Zentaris Announces Outcome of Managements Strategic Review
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
6. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
7. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
8. AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
9. AEterna Zentaris and Paladin Labs Announce Sale and Purchase of Miltefosine Rights
10. Aeterna Zentaris Reports Fourth Quarter and Full-Year 2007 Financial and Operating Results
11. Aeterna Zentaris Begins Second Phase 3 Trial of Cetrorelix for Benign Prostatic Hyperplasia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ceres, Inc . (Nasdaq: CERE ), an ... for the three months ended May 31, 2014 and ... reported that the company and its customers have made ... Brazil, which concluded in June, despite dry and hot ... part of the growing season. Yields of several of ...
(Date:7/10/2014)... today in the journal PNAS (Proceedings of the ... of day and sleep deprivation have a significant effect ... looking at the best time of day to test ... for administering medicines effectively. , Researchers from the University ... investigated the links between sleep deprivation, body clock disruption ...
(Date:7/10/2014)... geckos and spiders can sit upside down forever. Nanophysics makes ... this in an article just published in Physical Review ... , Geckos and spiders that seem to be able to ... researchers worldwide for many years. We will soon be able ... as the gecko,s foot. But the fact is, sooner or ...
(Date:1/15/2014)... assembling a club sandwich at the nanoscale, National ... succeeded in crafting a uniform, multi-walled carbon-nanotube-based coating ... used in upholstered furniture and other soft furnishings. ... was reduced 35 percent compared with untreated foam. ...
Breaking Biology Technology:Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Time of day crucial to accurately test for diseases, new research finds 2Even geckos can lose their grip 2Layered security: Carbon nanotubes promise improved flame-resistant coating 2
... allows up to 50% sucrose reduction while maintaining the sweet taste ... ... CA, July 29, 2008 Senomyx, Inc.,(Nasdaq: SNMX ), a ... flavor ingredients for the food, beverage,and ingredient supply industries, announced today ...
... technology to an,orphan disease, in a unique translational ... July 29 ,ALS Therapy Development Institute (ALS TDI) ... new collaboration aimed at advancing any potential,application of ... sclerosis,commonly known as Lou Gehrig,s diseases. The new ...
... Zenobia Therapeutics, Inc.,(Zenobia) announced today that ... from The Michael J. Fox Foundation for ... potential to,fundamentally alter the course of Parkinson,s ... Ross of Johns Hopkins University,Zenobia will discover ...
Cached Biology Technology:SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 2SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 3SENOMYX ANNOUNCES INITIATION OF DEVELOPMENT ACTIVITIES FOR NEW SUCROSE ENHANCER 4ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration 2ALS Therapy Development Institute and California Stem Cell, Inc. Announce Long-Term Scientific Collaboration 3Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinson's Research Award for Work on PD-implicated Protein LRRK2 2
(Date:7/10/2014)... JUPITER, FL, July 10, 2014 Amidst the astounding ... of synaptic connections in the brain, how do nerve ... connections to build? How do they coordinate these events ... scientists from the Florida campus of The Scripps Research ... processes, showing that a particular protein plays a far ...
(Date:7/10/2014)... Amyloid diseases, such as Alzheimer,s disease, type 2 ... the common trait that proteins aggregate into long ... studies have found that neither the amylin monomer ... New evidence using two-dimensional infrared (2D IR) spectroscopy ... aggregation pathway that may explain toxicity, opening a ...
(Date:7/10/2014)... Ore. Nuclear engineers at Oregon State University have ... device that should help people all over the world ... intensity, and whether or not it poses a health ... to public demand following the nuclear incident in Fukushima, ... what level of radiation they were being exposed to ...
Breaking Biology News(10 mins):Scripps Florida scientists shed new light on nerve cell growth 2New technology reveals insights into mechanisms underlying amyloid diseases 2Sophisticated radiation detector designed for broad public use 2Sophisticated radiation detector designed for broad public use 3
... Lee Lovering, Ph.D., School of Biosciences, University of ... Award for his seminal work on the structural ... and modify cell walls in bacteria. Natalie Strynadka, ... Lovering,s work: "his spectacular abilities in structural biology ...
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... risks posed to people who work with tiny fibres used ... Research into the health risks posed by nanofibres ... has pinpointed the lengths at which these fibres are ... from a range of materials including carbon, are about 1,000 ...
Cached Biology News:The American Society for Microbiology honors Andrew Lovering 2As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2